ReviewFrontiers in neurology2023
Uric acid and neurological disease: a narrative review.
Review in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Uric Acid in Cerebral Ischemia: A Systematic Review of Its Biomarker Value and Role in Neuroprotection.International journal of molecular sciences · 2025Pooled it
- Association between gout, hyperuricemia, and Parkinson's disease: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- Potential of Saliva in Stroke Patients: A Review.International journal of molecular sciences · 2026Review
- Age-dependent association of uric acid levels with depressive symptoms in adults: NHANES 2007-2018.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Hyperuricemia aggravates acute pancreatitis through CNR1-mediated inflammatory signaling and gut-pancreas axis dysregulation: a multi-omics and clinical study.Scientific reports · 2026Article
- Serum albumin and uric acid: biomarkers of neurocognitive and physical function in early Parkinson's disease.Experimental brain research · 2026Article
- Synthesis of ZnO/SnOJournal of fluorescence · 2026Article
- Albiflorin-Mediated MAP2K1 Targeting and HIF-1 Signaling Inhibition Contribute to the Therapeutic Efficacy in Hyperuricemia-Associated Cognitive Impairment.Human mutation · 2026Article
- Inflammatory Response Indices in Patients with Acute Ischemic Stroke Treated with and Without Reperfusion Therapy.Journal of clinical medicine · 2025Article
- Uric acid and ammonia play synergistic roles in the loss of blood-brain barrier integrity in the context of hepatic encephalopathy.Fluids and barriers of the CNS · 2025Article
- The association between calcium-phosphorus product and hyperuricemia varied in BMI groups: a mediation analysis study.Clinical rheumatology · 2025Article
- Association of uric acid to high-density cholesterol ratio (UHR) with biological age acceleration: evidence from NHANES 2009-2018.Scientific reports · 2025Article
- Uric Acid and Impulse Control Disorders in Parkinson's Disease: A Cross-Sectional Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Wearable biomolecular sensing nanotechnologies in chronic disease management.Nature nanotechnology · 2025Review
- Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms.Expert review of neurotherapeutics · 2025Review
- Exploring the Role of Diabetes in ALS: A Population-Based Cohort Study.Life (Basel, Switzerland) · 2025Article
- Xanthine Oxidoreductase: A Double-Edged Sword in Neurological Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Targeting uric acid: a promising intervention against oxidative stress and neuroinflammation in neurodegenerative diseases.Cell communication and signaling : CCS · 2025Review
- Uric acid and HDL-C-derived inflammatory ratios as biomarkers in schizophrenia and major depressive disorder: a retrospective study.Frontiers in psychiatry · 2025Article
- Beneficial and Detrimental Effects of Uric Acid on Alzheimer's Disease.Current neuropharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia often accompanies hypertension, diabetes, dyslipidemia, metabolic syndrome, and chronic renal disease; it is also closely related to cardiovascular disease. Moreover, several epidemiological studies have linked hyperuricemia and ischemic stroke. However, uric acid may also have neuroprotective effects because of its antioxidant properties. An association between low uric acid levels and neurodegenerative diseases has been suggested, which may be attributed to diminished neuroprotective effects as a result of reduced uric acid. This review will focus on the relationship between uric acid and various neurological diseases including stroke, neuroimmune diseases, and neurodegenerative diseases. When considering both the risk and pathogenesis of neurological diseases, it is important to consider the conflicting dual nature of uric acid as both a vascular risk factor and a neuroprotective factor. This dual nature of uric acid is important because it may help to elucidate the biological role of uric acid in various neurological diseases and provide new insights into the etiology and treatment of these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.